Skip to content

Intracerebral Hemorrhage Due to Oral Anticoagulants: Prediction of the Risk by Magnetic Resonance

Intracerebral Hemorrhage Due to Oral Anticoagulants in the Secondary Prevention of Ischemic Stroke: Prediction of the Risk by the Detection of Leukoaraiosis and Microbleeding With Magnetic Resonance

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02238470
Acronym
HERO
Enrollment
1000
Registered
2014-09-12
Start date
2012-04-30
Completion date
2017-09-30
Last updated
2018-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Stroke

Keywords

Ischemic stroke, Intracerebral hemorrhage, Subdural hemorrhage, Microbleed, Leukoaraiosis, Oral anticoagulants

Brief summary

The purpose of this study is to determine whether Magnetic Resonance Imaging may predict the risk of Intracerebral Hemorrhage for patients with ischemic stroke who receive indefinite oral anticoagulation

Detailed description

OBJECTIVES. To evaluate whether Magnetic Resonance (MR) helps in predicting the risk of Intracranial Hemorrhage (ICH-OA) in patients with ischemic stroke who will receive Oral Anticoagulants (OA) for the secondary prevention of stroke. By allowing the detection and quantification of leukoaraiosis and microbleeding, MR aids in the assessment of hypertensive and/or amyloid angiopathy, two findings that may increase the risk of ICH-OA. The study of these and other known variables associated with the risk of ICH-OA will improve the selection of patients to be treated with OA. METHODOLOGY. A prospective, observational, multicentric study of 1000 patients with stroke, older than 65 y, candidates to receive OA indefinitely. The primary end-point is ICH-OA. A MR will be performed before starting the treatment, in which we will evaluate the presence and degree of leukoaraiosis (Fazekas's scale) and microbleeding (BOMBS scale). A visit will be scheduled at the first month after inclusion, and thereafter the patient will be followed-up during 2 years with phone interviews, to evaluate the appearance of the primary end-point. We will register data about demographics, vascular risk factors, anticoagulation, MR, echocardiography and co-morbidity. With those variables associated with ICH-OA in the univariate analyses, a regression analysis will be performed, in which ICH-OA will be the dependent variable. Finally, each independent predictive variable will receive a score to elaborate a predictive model of ICH-OA.

Interventions

DRUGoral anticoagulants

Comparison of patients receiving oral anticoagulants with or without microbleeds in magnetic resonance imaging

Sponsors

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age \> 65 y 2. TIA or ischemic stroke 3. The patient will receive indefinitely treatment with oral anticoagulants for the secondary prevention of cardioembolic stroke 4. No previous treatment with oral anticoagulants 5. Signed consent before performing a Magnetic Resonance 6. Long-term follow-up will be possible

Exclusion criteria

1. The patient will receive oral anticoagulation as a primary prevention treatment 2. The etiology that motivates the onset of oral anticoagulants is not cardioembolism 3. Absolute contraindication to receive oral anticoagulants 4. Arterial hypertension that is not controlled, hypertensive crisis 5. Dementia 6. Live-expectancy less than 1 year 7. Any social or psychological reason that prevents follow-up 8. Contraindication to perform a Magnetic Resonance examination 9. Patients who received oral antiacoagulants prior to the current stroke 10. The Magnetic Resonance imaging was performed more than 1 month after the onset of treatment with oral anticoagulants

Design outcomes

Primary

MeasureTime frameDescription
Intracranial Hemorrhageevery 3 months after stroke, until 24 monthsTelephone interview every 3 months, starting 3 months after ischemic stroke (3, 6, 9, 12, 15, 18, 21 and 24 months)

Secondary

MeasureTime frame
Ischemic strokewithin 24 months after inclusion

Countries

Italy, Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026